Kura Oncology to Report Third Quarter Financial Results on November 10
Globe Newswire•03/11/2026•06:58 ET
0
Key Highlights
- ➤Kura reports third-quarter 2026 financial results November 10 after market close
- ➤Management hosts results webcast and conference call at 4:30 p.m. ET
- ➤KOMZIFTI is FDA-approved for relapsed or refractory NPM1-mutated acute myeloid leukemia
SAN DIEGO, Nov. 03, 2026 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a biopharmaceutical company focused on precision medicines for the treatment of cancer, today announced it will report its third quarter 2026 financial results after market close on Tuesday, November 10, 2026.
Kura’s management will host a webcast and conference call at 4:30 p.m. ET / 1:30 p.m. PT to discuss the results and provide a corporate update.
Get started
Create a free account to read the full story.